Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
5.95
0.00 (0.00%)
Market open: Aug 12, 2026, 2:22 PM EDT
5.95
0.00 (0.00%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
| Name | Position |
|---|---|
| Dr. Robert Bell Ph.D. | Co-Founder & Chief Science Officer |
| Mr. Alexander A. Fitzpatrick Esq. | Chief Legal Officer & Secretary |
| Mr. Brian T. Dorsey M.S. | Chief Operating Officer |
| Mr. Daniel Relovsky | Senior Vice President of Marketing |
| Mr. Donn Casale | CEO, President & Director |
| Mr. Eric Karas | Chief Commercial Officer |
| Mr. Justin Chakma | Chief Business Officer |
| Ms. Kathleen D. Scott CPA | Chief Financial Officer |
| Ms. Lynda Harris | Vice President of Human Resources |
| Date | Type | Document |
|---|---|---|
| 2026-07-17 | 8-K | d168709d8k.htm |
| 2026-07-07 | 8-K | d157645d8k.htm |
| 2026-06-25 | 8-K | d26870d8k.htm |
| 2026-05-15 | 8-K | spry-20260515.htm |
| 2026-05-15 | 10-Q | spry-20260331.htm |
| 2026-05-13 | 8-K | d10320d8k.htm |
| 2026-04-29 | DEFA14A | spry_fy2026_defa14a.htm |
| 2026-04-29 | DEF 14A | spry-20260429.htm |
| 2026-04-29 | ARS | spry_fy2026_ars.pdf |
| 2026-03-09 | S-8 | spry-20260309.htm |